ispinesib
Small moleculeexperimental
Clinical trial activity
16 trials · 11 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
10
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2003 (NCT00085813)
Timeline
Indications
Studied for
- Anemia, Refractory · Phase 1
- Astrocytoma · Phase 1
- Brain Neoplasms · Phase 1
- Breast Neoplasms · Phase 2
- Burkitt Lymphoma · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Renal Cell · Phase 2
- Carcinoma, Squamous Cell · Phase 2
- Carcinoma, Verrucous · Phase 2
- Choroid Plexus Neoplasms · Phase 1
- Colonic Neoplasms · Phase 2
- Colorectal Neoplasms · Phase 2
- Craniopharyngioma · Phase 1
- Ependymoma · Phase 1
- Glioma · Phase 1
- Graft vs Host Disease · Phase 2
- Hodgkin Disease · Phase 1
- Leukemia · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1
- Leukemia-Lymphoma, Adult T-Cell · Phase 1
- Leukemia, Monocytic, Acute · Phase 1
- Leukemia, Myeloid, Acute · Phase 1
- Leukemia, Myeloid, Chronic-Phase · Phase 1
- Leukemia, Myelomonocytic, Acute · Phase 1
- Liver Neoplasms · Phase 2
- Lymphoma · Phase 1
- Lymphoma, B-Cell, Marginal Zone · Phase 1
- Lymphoma, Follicular · Phase 1
- Lymphoma, Large B-Cell, Diffuse · Phase 1
- Lymphoma, Large-Cell, Immunoblastic · Phase 1
- Lymphoma, Mantle-Cell · Phase 1
- Lymphoma, Primary Cutaneous Anaplastic Large Cell · Phase 1
- Lymphomatoid Granulomatosis · Phase 1
- Medulloblastoma · Phase 1
- Melanoma · Phase 2
- Meningioma · Phase 1
- Myelodysplastic Syndromes · Phase 1
- Neoplasm Metastasis · Phase 2
- Neoplasms · Phase 1
- Neoplasms, Germ Cell and Embryonal · Phase 1
- Neuroectodermal Tumors · Phase 1
- Ovarian Neoplasms · Phase 2
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Phase 1
- Prostatic Neoplasms · Phase 2
- Salivary Gland Neoplasms · Phase 2
- Spinal Cord Neoplasms · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Waldenstrom Macroglobulinemia · Phase 1
Mechanism of action
- Kinesin-like protein 1INHIBITOR
KIF11 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1ccc(C(=O)N(CCCN)[C@@H](c2nc3cc(Cl)ccc3c(=O)n2Cc2ccccc2)C(C)C)cc1- Mol. weight
- 517.07 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL228814 ↗
Also known as
- ispinesib
- ispinesib
- ispinesib
- sb715992
- sb 715992
- sb-715992
- sb-715992
- sb-715992
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00607841 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2007 | Cytokinetics |
| NCT00363272 | Phase 1 | Jun 1, 2006 | National Cancer Institute (NCI) |
| NCT00354250 | Phase 2 | May 1, 2006 | National Cancer Institute (NCI), University of Chicago |
| NCT00096499 | Phase 2 | Apr 1, 2005 | National Cancer Institute (NCI), Southwest Oncology Group |
| NCT00095628 | Phase 2 | Jan 1, 2005 | National Cancer Institute (NCI), University of Toronto |
| NCT00103311 | Phase 2 | Jan 1, 2005 | National Cancer Institute (NCI), University of Southern California |
| NCT00097409 | Phase 2 | Dec 1, 2004 | GlaxoSmithKline |
| NCT00098826 | Phase 1 | Dec 1, 2004 | Case Western Reserve University, National Cancer Institute (NCI) |
| NCT00101244 | Phase 1 | Nov 1, 2004 | National Cancer Institute (NCI), Wayne State University |
| NCT00095953 | Phase 2 | Nov 1, 2004 | British Columbia Cancer Agency, Canadian Cancer Trials Group, National Cancer Institute (NCI) |
| NCT00095992 | Phase 2 | Nov 1, 2004 | British Columbia Cancer Agency, Canadian Cancer Trials Group, National Cancer Institute (NCI), University of Toronto |
| NCT00119171 | Phase 1 | Nov 1, 2004 | GlaxoSmithKline |
| NCT00136578 | Phase 1 | Oct 1, 2004 | GlaxoSmithKline |
| NCT00169520 | Phase 1 | Jun 1, 2004 | GlaxoSmithKline |
| NCT00089973 | Phase 2 | Jun 1, 2004 | GlaxoSmithKline |
| NCT00085813 | Phase 2 | Dec 1, 2003 | GlaxoSmithKline |
Showing 16 of 16 trials
Page 1 / 1
Organizations
Research & Development (11)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 9 | 7 | 2 | 2004 |
| GlaxoSmithKline | For profit | 6 | 6 | 2 | 2003 |
| British Columbia Cancer Agency | Academic/Hospital | 2 | 0 | 1 | 2004 |
| Canadian Cancer Trials Group | Academic/Hospital | 2 | 2 | 1 | 2004 |
| University of Toronto | Academic/Hospital | 2 | 0 | 1 | 2004 |
| Case Western Reserve University | Academic/Hospital | 1 | 0 | 1 | 2004 |
| Cytokinetics | For profit | 1 | 1 | 1 | 2007 |
| Southwest Oncology Group | Academic/Hospital | 1 | 0 | 1 | 2005 |
| University of Chicago | Academic/Hospital | 1 | 0 | 1 | 2006 |
| University of Southern California | Academic/Hospital | 1 | 0 | 1 | 2005 |
| Wayne State University | Academic/Hospital | 1 | 0 | 1 | 2004 |
11 organizations
Page 1 / 1